Viking Therapeutics stock plunged late Wednesday on an earnings report that included mostly incremental updates for its weight-loss drugs.

Viking thinks the oral alternative offers a smooth transition from the subcutaneous form and might appeal to individuals reluctant about injectable therapies. The business completed an End-of-Phase 2 meeting with the FDA in the fourth quarter to get comments on its Phase 3 preparations.

We recently published a list of 15 Stocks That Took a Nosedive in January. In this article, we are going to take a look at where Viking Therapeutics, Inc. (NASDAQ:VKTX) stands against other stocks that took a nosedive in January.